MedTrace Logo

Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)

NCT00092716 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 655

Last updated 2024-08-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether an investigational medication will be more effective than an approved medication in reducing cholesterol levels.

Conditions

Interventions

DRUG

MK0653, ezetimibe / Duration of Treatment: 28 weeks

DRUG

Comparator: atorvastatin / Duration of Treatment: 28 weeks

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-05-31
Primary Completion
2003-04-30
Completion
2003-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00092716 on ClinicalTrials.gov